Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
July 22 -- Drug and device manufacturers and group purchasing organizations that fail to validate the accuracy of their spending data prior to submitting it to the Centers for Medicare & Medicaid Services' Open Payments program are courting potential fines and reputational risks, according to a speaker at July 22 webinar.
The CMS can audit data submissions to the Open Payments program at any time, Jeff Fisher, a manager with Huron Life Sciences, said during the webinar, and civil monetary penalties (CMPs) for failing to report data in an accurate and timely fashion can range from $1,000 to $10,000 per transaction.
CMPs for knowing failures to report data in an accurate and timely fashion can range from $10,000 to $100,000 per transaction, Fisher said.
The Open Payments program, also known as the Sunshine Act, requires manufacturers of drugs, devices and other medical supplies and group purchasing organizations to report certain payments to physicians or teaching hospitals.
Huron Life Sciences is a unit of Huron Consulting, which is based in Chicago.
In addition to the threat of CMPs, submitted spending data can also be accessed by the Department of Justice, the Department of Health and Human Services Office of Inspector General and the Securities and Exchange Commission, Fisher said, increasing the risk that inaccurate submissions may prompt government investigations.
The lack of validated Open Payments submissions can lead to the appearance of kickbacks, reputational damage and the appearance of inappropriate interactions with health-care providers, Fisher said.
Under the program, payment data for the past five months of 2013 were due to the CMS June 30, and the data will be available to the public no later than Sept. 30.
Fisher said that data submission errors can stem from problems in three related areas: the source system, the customer master file and the Open Payments template itself.
Source systems are used by companies to collect their aggregate spending data, and can occasionally fail to extract full payment data, he said.
For example, a source system might classify a physician as a business guest and not extract any payment data surrounding the transaction.
Additionally, source systems often fail to extract all reportable payment data and sometimes capture data inaccurately, Fisher said.
As for the customer master file, data accuracy is only a good as what's in the file, he said.
Common errors include misidentifying physicians and the absence of key identifiers, such as a National Provider Identifier or a state license number.
Also, the very act of entering spending data into the Open Payments template can introduce error, Fisher said, due to a failure to fill in all required fields.
To eliminate the risk of CMPs and reduce data submission errors, Fisher said companies should engage in a four-step data validation process, beginning by analyzing source system data and validating that the data are accurate.
As a second step, companies should identify the root cause for any spending data errors and create procedures to correct them. Once errors have been identified and new procedures created, a third step should involve implementing the new procedures, Fisher said.
Finally, companies should focus on employee education, ensuring that employees are cognizant of the root causes behind spending data errors and aware of the potential consequences for inaccurate data submissions.
Looking to the future, Fisher said that data analytics surrounding Open Payments submissions is becoming increasingly sought after.
Data analytics can result in internal data certification, validation and monitoring, operational insights and risk analysis, he said.
To facilitate proper data analytics, payment data must be kept in one place and updated frequently, Fisher said.
To contact the reporter on this story: James Swann in Washington at email@example.com
To contact the editor responsible for this story: Ward Pimley at firstname.lastname@example.org
More information about Open Payments is at http://www.cms.gov/Regulations-and-Guidance/Legislation/National-Physician-Payment-Transparency-Program/index.html.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)